Clinical Trials Logo

Clinical Trial Summary

The primary goal of this pilot study is to investigate the association between testosterone deficiency and the presence of abnormalities in the function of the autonomic nervous system. If such association exists, then we will investigate the effect of testosterone replacement therapy on correcting these abnormalities.


Clinical Trial Description

The investigators will recruit 40 men between the ages of 40 to 80-years-old with low testosterone. Participants will be selected among those males referred to the Texas Tech University Health Sciences Center's (TTUHSC's) Internal Medicine Endocrinology Division outpatient clinic for the study and management of testosterone deficiency and to the TTUHSC Urology Department for diagnosis and management of prostate cancer that will result in testosterone deficiency due to surgical or pharmacological castration.

After recruitment, patients will have an initial standard clinical visit where aspects such as fatigue and anxiety will be investigated, followed by a full battery of autonomic testing (tilt table, heart rate response to deep breathing, Valsalva, and the Quantitative Sudomotor Axon Reflex Test (QSART).

Those patients with an initial diagnosis of testosterone deficiency will be initiated on testosterone replacement (intramuscular or skin routes) as standard of care, followed by a second visit in three (3) months--after normalization of serum testosterone levels--to evaluate changes in anxiety and fatigue level, and to repeat the cardiovascular autonomic function test.

Those patients with primary diagnosis of prostate cancer and normal serum testosterone levels will be evaluated a second time after confirmation of low testosterone, as described above. Standard questionnaires will be used to evaluate fatigue and anxiety. The autonomic testing of the heart will include tilt table (tilt the patient 70 degree by special designed table) and heart rate response to deep breathing, and Valsalva maneuver. Descriptive statistics will be compared between before and after treatment using different statistical methods. ;


Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02715713
Study type Observational
Source Texas Tech University Health Sciences Center
Contact
Status Withdrawn
Phase N/A
Start date March 2016
Completion date August 2016

See also
  Status Clinical Trial Phase
Completed NCT01446042 - Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism Phase 3
Completed NCT02966652 - Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism Phase 1
Completed NCT01228071 - Time to Eugonadal Range, Time to Steady State and Drying Time Phase 3
Completed NCT00858650 - Registry of Hypogonadism in Men N/A
Recruiting NCT05541172 - Testosterone Undecanoate Replacement Therapy in Boys With Pubertal Delay or Confirmed Hypogonadism
Not yet recruiting NCT04704141 - Relationship of the Microenvironment and Male Fertility
Completed NCT01403116 - Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men Phase 3
Completed NCT00924612 - Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation Phase 2
Completed NCT00911586 - Pharmacokinetic Study to Determine Time to Steady-state Phase 2
Completed NCT01765179 - Safety and Efficacy Trial of Testosterone Undecanoate Phase 3
Completed NCT00475501 - 5-Alpha Reductase and Anabolic Effects of Testosterone Phase 2
Completed NCT04708249 - D-chiroinositol Administration in Hypogonadal Males N/A
Completed NCT02081300 - Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism Phase 3
Active, not recruiting NCT03721497 - Testosterone in Bariatric Patients Phase 4
Completed NCT01699178 - Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men Phase 3